7 NOVEMBER 2023 - Can liquid biopsy be used to identify tumor markers? Servier has filed a new patent for this very purpose, and the exclusive rights have been entrusted to METHYS Dx, a French start-up with whom we have a long-standing partnership. This breakthrough is particularly targeted to patients with non-small cell lung cancer (NSCLC). Once again, this achievement demonstrates the importance of combining expertise to accelerate research.
A fruitful collaboration in liquid biopsy
METHYS Dx, a French start-up specializing in liquid biopsy, has obtained a patent license for the application of its technology to patients with non-small cell lung adenocarcinoma (NSCLC). This is the start-up’s 4th licensed patent, in addition to the first three for biomarkers targeting pancreatic, endometrial, and gastric cancer.
Did you know?
Non-small cell adenocarcinoma (or cancer) is one of the many forms of lung cancer. Originating in the cells on the outer surface of the lung, it is distinguished from small-cell lung cancer (SCLC) by the way the tumor cells appear under the microscope.
A long-term academic collaboration
In 2016, Servier teamed up with Université Paris Cité to develop a method for identifying biomarkers in lung cancer with liquid biopsy. Spearheaded by researcher Valérie Taly, and later giving rise to METHYS Dx, the work focuses primarily on the diagnosis, prognosis, and therapeutic follow-up of patients using an approach that is less invasive than tissue biopsies... Servier's Press Release -
